Relapse Number of participants having recurrence after stopping · patients on HD with HCV infection
Pegylated interferon alpha‐2a showed no clear difference in relapse(recurrence after stopping) compared with standard interferon (low certainty).
1 finding from 1 review
End‐of‐treatment response · patients on HD with HCV infection
Pegylated interferon alpha‐2a may leads to higher end‐of‐treatment response compared with standard interferon (low certainty).
1 finding from 1 review
Proportion with complete resolution of a target tophus · participants with tophi in gout
Pegloticase every two weeks (biweekly) probably leads to higher proportion with complete resolution of tophi compared with placebo (moderate certainty).
1 finding from 1 review
Joint pain reduction ‐ not reported · participants with tophi in gout
The review found no eligible studies for this question.
1 finding from 1 review
Quality of life ‐ not reported · participants with tophi in gout
The review found no eligible studies for this question.
1 finding from 1 review
Serum urate normalisation ‐ not reported · participants with tophi in gout
The review found no eligible studies for this question.
1 finding from 1 review
Function ‐ not reported · participants with tophi in gout
The review found no eligible studies for this question.
1 finding from 1 review
Withdrawals due to adverse events · participants with tophi in gout
Pegloticase every two weeks (biweekly) probably leads to higher number of participant withdrawals due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Total adverse events · participants with tophi in gout
Pegloticase every two weeks (biweekly) showed no clear difference in total adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Progression of Kaposi's sarcoma · HIV‐infected adults with severe (T1) Kaposi's sarcoma
1 finding from 1 review
Clinical response · HIV‐infected adults with severe (T1) Kaposi's sarcoma
HAART + pegylated liposomal doxorubicin showed no clear difference in clinical response compared with HAART alone (moderate certainty).
1 finding from 1 review
Change in visual acuity (logMAR) ‐ 12 months (negative is better) · adults with GA due to AMD
1 finding from 1 review
Change in untransformed GA lesion size from baseline at 1 year (mm²) · adults with GA due to AMD
1 finding from 1 review
Safety: Development of macular neovascularisation or exudative AMD at 1 year · adults with GA due to AMD
Summary of findings 3: Efficacy and safety of IVT pegcetacoplan… showed no clear difference in safety: Development of macular neovascularisation or exudative AMD… compared with sham; GRADE not reported.
1 finding from 1 review
Safety: Development of endophthalmitis at 1 year · adults with GA due to AMD
Summary of findings 3: Efficacy and safety of IVT pegcetacoplan… showed no clear difference in safety: Development of endophthalmitis at 1 year compared with sham (moderate certainty).
1 finding from 1 review
Loss of ≥ 15 letters BCVA at 1 year · adults with GA due to AMD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in LLVA from baseline at 1 year (ETDRS letters) · adults with GA due to AMD
1 finding from 1 review
QoL · adults with GA due to AMD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in visual acuity (logMAR) ‐ 12 months (negative is better) · adults with GA due to AMD
Summary of findings 4: Efficacy and safety of IVT pegcetacoplan… showed no clear difference in change in BCVA from baseline at 1 year (ETDRS letters) compared with sham (moderate certainty).
1 finding from 1 review
Change in untransformed GA lesion size from baseline at 1 year (mm²) · adults with GA due to AMD
1 finding from 1 review